Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea

Jeongha Mok, Hyungseok Kang, Won-Jung Koh, Byung Woo Jhun, Jae-Joon Yim, Nakwon Kwak, Taehoon Lee, Bohyoung Kang, Doosoo Jeon
European Respiratory Journal 2019 54: 1900811; DOI: 10.1183/13993003.00811-2019
Jeongha Mok
1Dept of Internal Medicine, Pusan National University Hospital, Pusan National University College of Medicine, Busan, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hyungseok Kang
2Dept of Chest Medicine, Masan National Tuberculosis Hospital, Masan, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Won-Jung Koh
3Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Won-Jung Koh
Byung Woo Jhun
3Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Byung Woo Jhun
Jae-Joon Yim
4Division of Pulmonary and Critical Care Medicine, Dept of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nakwon Kwak
4Division of Pulmonary and Critical Care Medicine, Dept of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taehoon Lee
5Dept of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Taehoon Lee
Bohyoung Kang
6Dept of Internal Medicine, Dong-A University Hospital, Busan, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doosoo Jeon
7Dept of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University College of Medicine, Yangsan, South Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sooli10@hanmail.net
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Extract

A phase III trial of delamanid showed acceptable safety and tolerability; however, it failed to demonstrate superior efficacy of delamanid in terms of reduction in time to sputum conversion and improvement in final treatment outcomes compared with placebo [1]. How to interpret these results and identify the role of delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment is challenging [2]. Despite the disappointing results, this trial suggests that more studies are needed to better understand the role of delamanid in the current management of MDR-TB. So far, there have been several reports of real-world data on the interim outcomes of delamanid treatment [3–6], but few on its final outcomes [7].

Abstract

The optimised use of delamanid combined with effective repurposed drugs could achieve a high treatment success rate, even in pre-extensively drug-resistant (XDR)-TB and XDR-TB patients http://bit.ly/2plvEOT

Footnotes

  • Conflict of interest: J. Mok has nothing to disclose.

  • Conflict of interest: H. Kang has nothing to disclose.

  • Conflict of interest: W-J. Koh has nothing to disclose.

  • Conflict of interest: B.W. Jhun has nothing to disclose.

  • Conflict of interest: J-J. Yim has nothing to disclose.

  • Conflict of interest: N. Kwak has nothing to disclose.

  • Conflict of interest: T. Lee has nothing to disclose.

  • Conflict of interest: B. Kang has nothing to disclose.

  • Conflict of interest: D. Jeon has nothing to disclose.

  • Received April 23, 2019.
  • Accepted June 30, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 54 Issue 5 Table of Contents
European Respiratory Journal: 54 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea
Jeongha Mok, Hyungseok Kang, Won-Jung Koh, Byung Woo Jhun, Jae-Joon Yim, Nakwon Kwak, Taehoon Lee, Bohyoung Kang, Doosoo Jeon
European Respiratory Journal Nov 2019, 54 (5) 1900811; DOI: 10.1183/13993003.00811-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea
Jeongha Mok, Hyungseok Kang, Won-Jung Koh, Byung Woo Jhun, Jae-Joon Yim, Nakwon Kwak, Taehoon Lee, Bohyoung Kang, Doosoo Jeon
European Respiratory Journal Nov 2019, 54 (5) 1900811; DOI: 10.1183/13993003.00811-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Clump material within drainage chest tubes contains diagnostic information
  • Leukocyte telomere length and mycophenolate therapy in CHP
  • Connexins and the pulmonary vascular response to hypoxia
Show more Agora

Research letters

  • Clump material within drainage chest tubes contains diagnostic information
  • Leukocyte telomere length and mycophenolate therapy in CHP
  • Connexins and the pulmonary vascular response to hypoxia
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society